CLINICAL TRIALS PROFILE FOR POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
✉ Email this page to a colleague
All Clinical Trials for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04051580 ↗ | Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia | Completed | Mahidol University | N/A | 2019-08-05 | Del Nido cardioplegia has been used exclusively for myocardial protection in pediatrics cardiac surgery for decades. Its unique properties including lidocaine which helps counteract potassium depolarization of the myocardial cell membrane, inhibition of intracellular calcium accumulation, preservation of intracellular high-energy phosphates, free-radical scavenging and acid-base buffering have been proven to be very effective for myocardial protection during cardiac surgery for congenital heart disease and acquired heart disease. Recent studies have proven its safety, efficacy, and cost-effectiveness for myocardial protection in adult cardiac surgery as a single dose cardioplegia which is typically administered in a single dose fashion or with extended dosing intervals. In contrast, Traditional blood cardioplegia is commonly administered approximately every 20 minutes. These characteristics of del Nido cardioplegia allow for fewer interruptions and improve surgical workflow. The base solution for del Nido cardioplegia is normally Plasma-Lyte A (Baxter Healthcare Corporation, Deerfield, IL, USA) which has an electrolyte composition similar to the extracellular fluid and is calcium-free. Unfortunately, an unavailability of PlasmaLyte-A in many countries precluding utilization of del Nido cardioplegia with its normal base solution in many cardiac centers. To access the benefits of del Nido cardioplegia, we utilize lactated Ringer's solution as the base solution. This prospective randomized study aimed to evaluate myocardial preservation and clinical outcomes when using lactated Ringer's solution compared with PlasmaLyte-A as a base solution for del Nido cardioplegia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Condition Name
Clinical Trial Locations for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Clinical Trial Progress for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Sponsor Name
